Addition of platinum compounds to a new agent in patients with advanced non-smal-cell lung cancer

A literature based meta-analysis of randomised trials

Katsuyuki Hotta, K. Matsuo, H. Ueoka, Katsuyuki Kiura, Masahiro Tabata, M. Tanimoto

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Background: Single new agents reportedly produce promising response and survival effects, but platinum-based doublets remain the standard chemotherapy for advanced non-small-cell lung cancer (NSCLC). The aim of this study was to evaluate the effectiveness of platinum for advanced NSCLC by carrying out a meta-analysis of trials that compared platinum-based doublets with single new agent therapy alone. Methods: We carried out a literature search to identify trials, conducted between 1994 and 2003, comparing a doublet of platinum plus a new agent with a new agent alone in previously untreated patients with advanced NSCLC. Outcomes analysed were response, survival and toxicity. Results: Eight trials encompassing 2374 patients were identified. Platinum-based doublets produced an approximately two-fold higher overall (complete and partial) response rate than the new agent alone [odds ratio = 2.32; 95% confidence interval (CI) = 1.68-3.20]. Platinum-based doublet therapy was also associated with a 13% prolongation of survival (hazard ratio = 0.87; 95% CI = 0.80-0.94, P

Original languageEnglish
Pages (from-to)1782-1789
Number of pages8
JournalAnnals of Oncology
Volume15
Issue number12
DOIs
Publication statusPublished - Dec 2004

Fingerprint

Platinum Compounds
Proxy
Platinum
Meta-Analysis
Lung Neoplasms
Non-Small Cell Lung Carcinoma
Survival
Confidence Intervals
Odds Ratio
Drug Therapy
Therapeutics

Keywords

  • Doublets
  • Non-small-cell lung cancer
  • Platinum
  • Single-agent therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{4cd12fcf325b4885b93997a3bfb295b0,
title = "Addition of platinum compounds to a new agent in patients with advanced non-smal-cell lung cancer: A literature based meta-analysis of randomised trials",
abstract = "Background: Single new agents reportedly produce promising response and survival effects, but platinum-based doublets remain the standard chemotherapy for advanced non-small-cell lung cancer (NSCLC). The aim of this study was to evaluate the effectiveness of platinum for advanced NSCLC by carrying out a meta-analysis of trials that compared platinum-based doublets with single new agent therapy alone. Methods: We carried out a literature search to identify trials, conducted between 1994 and 2003, comparing a doublet of platinum plus a new agent with a new agent alone in previously untreated patients with advanced NSCLC. Outcomes analysed were response, survival and toxicity. Results: Eight trials encompassing 2374 patients were identified. Platinum-based doublets produced an approximately two-fold higher overall (complete and partial) response rate than the new agent alone [odds ratio = 2.32; 95{\%} confidence interval (CI) = 1.68-3.20]. Platinum-based doublet therapy was also associated with a 13{\%} prolongation of survival (hazard ratio = 0.87; 95{\%} CI = 0.80-0.94, P",
keywords = "Doublets, Non-small-cell lung cancer, Platinum, Single-agent therapy",
author = "Katsuyuki Hotta and K. Matsuo and H. Ueoka and Katsuyuki Kiura and Masahiro Tabata and M. Tanimoto",
year = "2004",
month = "12",
doi = "10.1093/annonc/mdh476",
language = "English",
volume = "15",
pages = "1782--1789",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Addition of platinum compounds to a new agent in patients with advanced non-smal-cell lung cancer

T2 - A literature based meta-analysis of randomised trials

AU - Hotta, Katsuyuki

AU - Matsuo, K.

AU - Ueoka, H.

AU - Kiura, Katsuyuki

AU - Tabata, Masahiro

AU - Tanimoto, M.

PY - 2004/12

Y1 - 2004/12

N2 - Background: Single new agents reportedly produce promising response and survival effects, but platinum-based doublets remain the standard chemotherapy for advanced non-small-cell lung cancer (NSCLC). The aim of this study was to evaluate the effectiveness of platinum for advanced NSCLC by carrying out a meta-analysis of trials that compared platinum-based doublets with single new agent therapy alone. Methods: We carried out a literature search to identify trials, conducted between 1994 and 2003, comparing a doublet of platinum plus a new agent with a new agent alone in previously untreated patients with advanced NSCLC. Outcomes analysed were response, survival and toxicity. Results: Eight trials encompassing 2374 patients were identified. Platinum-based doublets produced an approximately two-fold higher overall (complete and partial) response rate than the new agent alone [odds ratio = 2.32; 95% confidence interval (CI) = 1.68-3.20]. Platinum-based doublet therapy was also associated with a 13% prolongation of survival (hazard ratio = 0.87; 95% CI = 0.80-0.94, P

AB - Background: Single new agents reportedly produce promising response and survival effects, but platinum-based doublets remain the standard chemotherapy for advanced non-small-cell lung cancer (NSCLC). The aim of this study was to evaluate the effectiveness of platinum for advanced NSCLC by carrying out a meta-analysis of trials that compared platinum-based doublets with single new agent therapy alone. Methods: We carried out a literature search to identify trials, conducted between 1994 and 2003, comparing a doublet of platinum plus a new agent with a new agent alone in previously untreated patients with advanced NSCLC. Outcomes analysed were response, survival and toxicity. Results: Eight trials encompassing 2374 patients were identified. Platinum-based doublets produced an approximately two-fold higher overall (complete and partial) response rate than the new agent alone [odds ratio = 2.32; 95% confidence interval (CI) = 1.68-3.20]. Platinum-based doublet therapy was also associated with a 13% prolongation of survival (hazard ratio = 0.87; 95% CI = 0.80-0.94, P

KW - Doublets

KW - Non-small-cell lung cancer

KW - Platinum

KW - Single-agent therapy

UR - http://www.scopus.com/inward/record.url?scp=10944224661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10944224661&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdh476

DO - 10.1093/annonc/mdh476

M3 - Article

VL - 15

SP - 1782

EP - 1789

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 12

ER -